

Dec 25, 2020

**Award of the EPC Contract for a producing facility of a Vaccine Drug Substance
from SHIONOGI & CO., Ltd.**

Chiyoda Corporation (TSE:6366; ISIN: JP3528600004, Headquartered in Yokohama City, Kanagawa; President & COO : Masaji Santo; hereinafter: Chiyoda) have been awarded an EPC (Engineering, Procurement and Construction) contract for a producing facility of a Vaccine Drug Substance on the plant premises of UNIGEN Inc. in Gifu from SHIONOGI & CO., Ltd.(Headquartered: Osaka, Japan; President & CEO: Teshirogi Isao; hereinafter: “Shionogi”).

1. Client Name : SHIONOGI & CO., Ltd.
2. Construction Site : Ibi gun, Ikeda town, Gifu prefecture, Japan on the premises of manufacturing facility of UNIGEN Inc., in Gifu.
3. Job description : EPC work of a producing facility for a recombinant Protein Vaccine Drug Substance
4. Project Overview :

Shionogi has been pursuing the discovery and development of a recombinant protein vaccine for COVID-19, using a unique technology, BEVS*, established by UMN Pharma Inc., a subsidiary of Shionogi, and they initiated a Phase 1/2 clinical trial in Japan on December 16, 2020. Under such circumstance, Chiyoda have been awarded the EPC contract for construction of commercial producing system of the vaccine.

Through this project, Chiyoda construct a new producing line of the vaccine drug substance, on the facility premises of UNIGEN Inc., in Gifu, which was selected as a successful applicant of “Program for Promoting Investment in Japan to Strengthen Supply Chains” publicly established by the Ministry of Economy, Trade and Industry.

In addition, Chiyoda plan to conduct a construction for expansion of commercial producing system in 2021, which was adopted by the Ministry of Health, Labor and Welfare as a subsidies project for “An Urgent Improvement project for Vaccine manufacturing System”

We aim for the earliest end of the COVID-19, which is causing enormous damage to economies and people’s health around the world, and as part of our initiatives for life science field, positioned as our growth field (strategy), we contribute through the use of our collective wisdom and painstakingly developed technology as an integrated engineering company.

*Baculovirus Expression Vector System

For more information, please contact:

Chiyoda Corporation

IR, PR & CSR Department

URL: <https://www.chiyodacorp.com/en/contact/index.php>